Bellevue Life Sciences Acquisition Past Earnings Performance
Past criteria checks 4/6
Bellevue Life Sciences Acquisition has been growing earnings at an average annual rate of 102.4%, while the Capital Markets industry saw earnings growing at 9.1% annually.
Key information
102.4%
Earnings growth rate
90.8%
EPS growth rate
Capital Markets Industry Growth | 10.3% |
Revenue growth rate | n/a |
Return on equity | n/a |
Net Margin | n/a |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Bellevue Life Sciences Acquisition makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 0 | 0 | 2 | 0 |
31 Dec 23 | 0 | 0 | 2 | 0 |
30 Sep 23 | 0 | 0 | 1 | 0 |
30 Jun 23 | 0 | 0 | 1 | 0 |
31 Mar 23 | 0 | 0 | 0 | 0 |
31 Dec 22 | 0 | 0 | 0 | 0 |
30 Sep 22 | 0 | 0 | 0 | 0 |
30 Jun 22 | 0 | 0 | 0 | 0 |
31 Mar 22 | 0 | 0 | 0 | 0 |
31 Dec 21 | 0 | 0 | 0 | 0 |
Quality Earnings: BLAC has high quality earnings.
Growing Profit Margin: Insufficient data to determine if BLAC's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BLAC's earnings have grown significantly by 102.4% per year over the past 5 years.
Accelerating Growth: BLAC's earnings growth over the past year (210.5%) exceeds its 5-year average (102.4% per year).
Earnings vs Industry: BLAC earnings growth over the past year (210.5%) exceeded the Capital Markets industry 8.9%.
Return on Equity
High ROE: BLAC's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.